Viking Global Investors LP

CIK: 0001103804

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (100.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

INBX

Inhibrx Biosciences, Inc.

10% Owner

BBIO

BridgeBio Pharma, Inc.

10% Owner

TIC

ACUREN CORP

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (5 total)

INBX
Inhibrx Biosciences, Inc.
Oct 7, 2025
Sale(S)
Indirect
308.6K shares at avg. $32.25$10.0M
INBX
Inhibrx Biosciences, Inc.
Oct 7, 2025
Sale(S)
Indirect
16.3K shares at avg. $32.25$526K
INBX
Inhibrx Biosciences, Inc.
Oct 7, 2025
Sale(S)
Indirect
25K shares at avg. $32.25$808K
BBIO
BridgeBio Pharma, Inc.
Jun 27, 2025
Sale(S)
Indirect
3.5M shares at avg. $44.00$154.0M
BBIO
BridgeBio Pharma, Inc.
Jan 31, 2025
Sale(S)
Indirect
3.1M shares at avg. $34.90$107.0M

		Type	Shares	Price		Ownership
Oct 7, 2025	INBX Inhibrx Biosciences, Inc.	Sale(S)	308,643	$32.25	$9,953,737	Indirect
Oct 7, 2025	INBX Inhibrx Biosciences, Inc.	Sale(S)	16,315	$32.25	$526,159	Indirect
Oct 7, 2025	INBX Inhibrx Biosciences, Inc.	Sale(S)	25,042	$32.25	$807,605	Indirect
Jun 27, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	3,500,000	$44.00	$154,000,000	Indirect
Jan 31, 2025	BBIO BridgeBio Pharma, Inc.	Sale(S)	3,065,616	$34.90	$106,989,998	Indirect

1-5 of 5 transactions

About VIKING GLOBAL INVESTORS LP

VIKING GLOBAL INVESTORS LP (SEC CIK 0001103804) files insider reports with the SEC as 10% Owner of Inhibrx Biosciences, Inc. (INBX), 10% Owner of BridgeBio Pharma, Inc. (BBIO) and 10% Owner of ACUREN CORP (TIC).

Signal8 holds 4 ownership filings by VIKING GLOBAL INVESTORS LP (1 Form 3, 3 Form 4), filed between Jan 31, 2025 and Oct 9, 2025. Those filings report 5 transactions, from Jan 31, 2025 to Oct 7, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on VIKING GLOBAL INVESTORS LP's filings is in STAMFORD, CT.

Recent filings by VIKING GLOBAL INVESTORS LP

Oct 7, 2025: Open-market sales of INBX shares (3 lines, Form 4, code S).
Jun 27, 2025: Open-market sale of BBIO shares (Form 4, code S).
Jan 31, 2025: Open-market sale of BBIO shares (Form 4, code S).

Other insiders filing for Inhibrx Biosciences, Inc. (INBX)

Lappe Mark, Chief Executive Officer
Kayyem Jon Faiz, Director
FORSYTH DOUGLAS, Director
Vuori Kristiina MD, Director
MANHARD KIMBERLY, Director
Matly David, President

How to read Form 4 transaction codes